Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Recruiting · NCT06580106 · Registry updated 2026-07-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-07-24 | NCT06580106 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Atrium Health Levine Cancer Institute | 27 |
| Swim Across America | 9 |
| Wake Forest University Health Sciences | 284 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Levine Cancer Institute | Charlotte | United States | 110 |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | United States | 26 |